30-day average of 4 articles Β· scale β100 to +100
Across 4 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of International Flavors & Fragrances news is Somewhat Bullish (+45)
on a scale from β100 to +100.
That is up 42 points from the previous 30 days (+3).
π IFF raised 2026 sales guidance to $7.5Bβ$7.6B and EBITDA to $1.55Bβ$1.6B.
π° Q3 revenue grew 5% while adjusted operating EBITDA rose 6% to $403 million.
Bullish +55
International Flavors & Fragrances Q3 Earnings Call Highlights
AI-generated analysis
Key insights
π IFF raised its lower-end guidance for 2026 sales to $7.5 billionβ$7.6 billion and adjusted operating EBITDA to $1.55 billionβ$1.6 billion following Q3 results.
π° Third-quarter revenue grew approximately 5% on a comparable currency-neutral basis, while adjusted operating EBITDA rose 6% to $403 million.
π« Taste and Scent segments both posted 6% sales growth, with Taste reaching $687 million and Scent reaching $689 million in the quarter.
𧬠Health & Biosciences sales increased 1% to $566 million as growth in Food Biosciences offset a decline in the health category.
β οΈ Fourth-quarter profitability is expected to face pressure from softer health volumes, higher input costs, and seasonal factors.
π Greater Asia led Taste segment growth with a double-digit increase, followed by high-single-digit growth in Latin America.
π IFF remains on track to close its $4.3 billion Food Ingredients sale to CVC Capital Partners by the end of H1 2027.
πΈ Free cash flow for the first nine months of the year rose to $371 million, reflecting improved operational efficiency.
π Net debt to adjusted EBITDA stood at 2.75 times at the end of Q3, up slightly due to an accelerated share repurchase.
π§ The company plans to eliminate about two-thirds of the $100 million in stranded costs from the Food Ingredients separation within 12 months.
π Bullish signals
πIFF raised its lower-end guidance for 2026 sales to $7.5 billionβ$7.6 billion and adjusted operating EBITDA to $1.55 billionβ$1.6 billion following strong Q3 performance.
π°Third-quarter revenue grew approximately 5% on a comparable currency-neutral basis, while adjusted operating EBITDA rose 6% to $403 million.
π«Both Taste and Scent segments achieved 6% sales growth in the quarter, with Taste reaching $687 million and Scent reaching $689 million.
π§¬Health & Biosciences segment sales increased 1% to $566 million as mid-single-digit growth in Food Biosciences offset a decline in health.
πGreater Asia led Taste segment growth with a double-digit increase, followed by high-single-digit growth in Latin America.
πΈFree cash flow for the first nine months of the year rose to $371 million, an increase of $245 million from a year earlier.
πThe company successfully completed a $500 million accelerated share repurchase, buying approximately 5.8 million shares.
π Risk factors
β οΈFourth-quarter profit margins are expected to decline sequentially due to softer health volumes, higher input costs, and seasonal factors.
β οΈHealth & Biosciences segment faces margin pressure from unfavorable pricing relative to input costs and timing of research investments.
πConsumers in the U.S. and Europe have reduced spending on dietary supplements amid economic pressure, impacting the Health & Biosciences segment.
β οΈThe gap between pricing and input costs is expected to be greatest in the first quarter of 2027 before improving through the year.
Article
International Flavors & Fragrances (IFF) raised its full-year 2026 outlook following a strong third quarter, projecting sales between $7.5 billion and $7.6 billion and adjusted operating EBITDA of $1.55 billion to $1.6 billion. The company reported third-quarter revenue growth of approximately 5% and an increase in adjusted operating EBITDA of 6%, driven by performance across its Taste, Scent, and Health & Biosciences segments.
IFF's Taste segment saw sales rise 6% to $687 million, with significant contributions from Greater Asia and Latin America. The Scent segment also achieved 6% sales growth to $689 million, supported by new business wins in Europe and North America. However, the Health & Biosciences segment grew only 1% due to reduced consumer spending on dietary supplements in the U.S. and Europe.
Looking ahead, IFF expects fourth-quarter margin pressure stemming from softer health volumes, higher input costs related to oil derivatives and energy, and seasonal factors. The company remains committed to closing its $4.3 billion sale of Food Ingredients by the end of the first half of 2027 and plans to eliminate approximately two-thirds of associated stranded costs within 12 months.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
International Flavors & Fragrances (IFF) raised its full-year 2026 outlook following a strong third quarter, projecting sales between $7.5 billion and $7.6 billion and adjusted operating EBITDA of $1.55 billion to $1.6 billion. The company reported third-quarter revenue growth of approximately 5% and an increase in adjusted operating EBITDA of 6%, driven by performance across its Taste, Scent, and Health & Biosciences segments.
IFF's Taste segment saw sales rise 6% to $687 million, with significant contributions from Greater Asia and Latin America. The Scent segment also achieved 6% sales growth to $689 million, supported by new business wins in Europe and North America. However, the Health & Biosciences segment grew only 1% due to reduced consumer spending on dietary supplements in the U.S. and Europe.
Looking ahead, IFF expects fourth-quarter margin pressure stemming from softer health volumes, higher input costs related to oil derivatives and energy, and seasonal factors. The company remains committed to closing its $4.3 billion sale of Food Ingredients by the end of the first half of 2027 and plans to eliminate approximately two-thirds of associated stranded costs within 12 months.
π IFF raised 2026 sales guidance to $7.5Bβ$7.6B and EBITDA to $1.55Bβ$1.6B.
π° Q3 revenue grew 5% while adjusted operating EBITDA rose 6% to $403 million.
π« Taste and Scent segments both posted 6% sales growth in the third quarter.
π Greater Asia led Taste segment growth with a double-digit increase this quarter.
π IFF remains on track to close its $4.3 billion Food Ingredients sale by H1 2027.
π IFF raised its lower-end guidance for 2026 sales to $7.5 billionβ$7.6 billion and adjusted operating EBITDA to $1.55 billionβ$1.6 billion following Q3 results.
π° Third-quarter revenue grew approximately 5% on a comparable currency-neutral basis, while adjusted operating EBITDA rose 6% to $403 million.
π« Taste and Scent segments both posted 6% sales growth, with Taste reaching $687 million and Scent reaching $689 million in the quarter.
𧬠Health & Biosciences sales increased 1% to $566 million as growth in Food Biosciences offset a decline in the health category.
β οΈ Fourth-quarter profitability is expected to face pressure from softer health volumes, higher input costs, and seasonal factors.
π Greater Asia led Taste segment growth with a double-digit increase, followed by high-single-digit growth in Latin America.
π IFF remains on track to close its $4.3 billion Food Ingredients sale to CVC Capital Partners by the end of H1 2027.
πΈ Free cash flow for the first nine months of the year rose to $371 million, reflecting improved operational efficiency.
π Net debt to adjusted EBITDA stood at 2.75 times at the end of Q3, up slightly due to an accelerated share repurchase.
π§ The company plans to eliminate about two-thirds of the $100 million in stranded costs from the Food Ingredients separation within 12 months.
Bullish Signals
Raised 2026 sales guidance to $7.5Bβ$7.6B and EBITDA to $1.55Bβ$1.6B.
Risk Factors
Q4 margins decline due to softer health volumes and higher costs.
Bullish Signals
IFF raised its lower-end guidance for 2026 sales to $7.5 billionβ$7.6 billion and adjusted operating EBITDA to $1.55 billionβ$1.6 billion following strong Q3 performance.
Third-quarter revenue grew approximately 5% on a comparable currency-neutral basis, while adjusted operating EBITDA rose 6% to $403 million.
Both Taste and Scent segments achieved 6% sales growth in the quarter, with Taste reaching $687 million and Scent reaching $689 million.
Health & Biosciences segment sales increased 1% to $566 million as mid-single-digit growth in Food Biosciences offset a decline in health.
Greater Asia led Taste segment growth with a double-digit increase, followed by high-single-digit growth in Latin America.
Free cash flow for the first nine months of the year rose to $371 million, an increase of $245 million from a year earlier.
The company successfully completed a $500 million accelerated share repurchase, buying approximately 5.8 million shares.
Risk Factors
Fourth-quarter profit margins are expected to decline sequentially due to softer health volumes, higher input costs, and seasonal factors.
Health & Biosciences segment faces margin pressure from unfavorable pricing relative to input costs and timing of research investments.
Consumers in the U.S. and Europe have reduced spending on dietary supplements amid economic pressure, impacting the Health & Biosciences segment.
The gap between pricing and input costs is expected to be greatest in the first quarter of 2027 before improving through the year.
International Flavors & Fragrances Inc. (IFF) reported a modest earnings beat for Q3 2026, with EPS of $0.83 surpassing the consensus estimate of $0.813. The company highlighted strength in its Taste and Scent segments, which are driving margin improvement initiatives and supporting analyst optimism. Despite this operational success, the stock faces headwinds from stretched valuation metrics and volatile earnings history.
IFF's financial profile presents a mixed outlook characterized by high leverage and cash flow challenges. The company carries approximately $6.83B in total debt against roughly $0.27B in cash, resulting in a mid-50% debt-to-equity ratio. While operating cash flow has recently turned positive at $1.14B, free cash flow remains negative due to capital spending and working capital pressures, raising questions about the durability of earnings.
Valuation concerns are significant, with IFF trading at a trailing P/E of 108.71x, well above historical averages and peer norms. The current price of $82.62 reflects depressed trailing earnings but implies a mid-30s P/E multiple if normalized earnings of $2.50 to $3.25 are achieved over the next 12-24 months. Analyst consensus remains Strong Buy with a mean price target near $98, suggesting potential upside contingent on successful margin recovery and deleveraging execution.
π IFF beat Q3 2026 EPS expectations at $0.83 versus $0.813 consensus.
πͺ Taste and Scent segments drove margin improvement efforts for the company.
β οΈ Total debt reaches $6.83B with only $0.27B in cash on hand.
π Trailing P/E ratio is elevated at 108.71x above historical averages.
π― Analysts rate IFF Strong Buy with a mean price target of $98.
π IFF delivered a Q3 2026 earnings beat with EPS of $0.83 versus the consensus of $0.813.
πͺ The Taste and Scent segments demonstrated strength, supporting management's focus on margin improvement.
β οΈ Total debt stands at approximately $6.83B while cash balances are around $0.27B.
π Free cash flow was negative in the referenced period due to capital spending and working capital moves.
π° The trailing P/E ratio is elevated at 108.71x, significantly above longer-term averages.
π― Analyst consensus rating is Strong Buy with a mean price target near $98 per share.
π Revenue growth remains modest at roughly 3.9% annually based on available data.
π Market share is significant globally, ranking #1-2 in the industry by revenue and scale.
π Stock price has pulled back 13.3% from its 52-week high of $95.27 as of November 6.
π Bull target is set at $108 (+30.7%) while the bear target is $70 (-15.3%).
π Next quarterly report is expected in early 2027 with a focus on updated full-year guidance.
π The company serves food, beverage, personal care, and industrial markets worldwide.
Bullish Signals
Q3 2026 EPS beat consensus at $0.83 vs $0.813.
Risk Factors
P/E of 108.71x is well above peer norms.
Bullish Signals
IFF reported a Q3 2026 earnings beat with EPS of $0.83, exceeding the consensus estimate of $0.813.
The Taste and Scent segments showed strength, supporting analyst optimism and margin improvement initiatives.
Analysts maintain a Strong Buy consensus rating with a mean price target near $98 per share.
Operating cash flow has recently turned positive at approximately $1.14B.
The company holds significant global market share, ranking #1-2 in the industry by revenue and scale.
Risk Factors
Stretched valuation metrics are evident with a trailing P/E of 108.71x, well above peer norms.
Negative free cash flow persists due to capital spending and working capital moves despite positive operating cash flow.
Elevated leverage is present with total debt around $6.83B and a mid-50% debt-to-equity ratio.
Earnings have been volatile in recent periods, posting negative net results in some annual reporting cycles.
The stock has traded below its 52-week high of $95.27, reflecting sector rotation and profit-taking.
International Flavors & Fragrances (IFF) reported strong third-quarter 2026 results, posting sales of $1.942 billion, a 4% year-over-year increase, and adjusted EBITDA of $403 million, up 5%. The company beat both sales and adjusted earnings per share expectations, driven by broad-based volume growth across its core divisions.
Segment performance was particularly robust in the Scent division, which saw adjusted EBITDA rise 10%, while the Taste division grew 7%. Currency-neutral sales growth was reported across all major segments including Health & Biosciences. Analysts have responded positively to the results, raising their average 12-month price target to $98.25 from $97.62, implying approximately 7% upside from the November 3 closing price.
Strategically, IFF completed its $500 million accelerated share repurchase program and agreed to sell its Food Ingredients business, with the transaction expected to close by the end of Q2 2027. While management flagged lower profitability in the fourth quarter due to higher costs and reinvestment needs in Health & Biosciences, the company maintains that its planned separation of the Food Ingredients unit remains on schedule for completion.
Market sentiment remains bullish with a consensus Buy rating among 16 analysts covering the stock. The price target range spans from $76 to $110, reflecting confidence in IFF's ability to navigate near-term margin pressures while executing its long-term growth strategy through organic volume gains and strategic divestitures.
π IFF Q3 sales rose 4% YoY to $1.942 billion.
π° Adjusted EBITDA increased 5% to $403 million.
π Company beat sales and EPS expectations on volume growth.
πΈ Completed $500M share repurchase program for capital return.
β οΈ Q4 profitability expected lower due to higher costs.
π IFF reported Q3 2026 sales of $1.942 billion, representing a 4% year-over-year increase.
π° Adjusted EBITDA reached $403 million in the quarter, marking a 5% increase from the prior year.
π The company beat both sales and adjusted EPS expectations driven by broad-based volume growth.
π Scent division adjusted EBITDA surged 10%, leading segment performance alongside 7% growth in Taste.
πΈ IFF completed its $500 million accelerated share repurchase program to return capital to shareholders.
π The Food Ingredients business was classified as discontinued operations with a sale expected to close in Q2 2027.
π Analysts raised the average 12-month price target to $98.25, implying about 7% upside from recent levels.
β οΈ Management flagged lower Q4 profitability due to higher costs and reinvestment needs in Health & Biosciences.
ποΈ The planned separation of the Food Ingredients unit remains on schedule for completion by end of Q2 2027.
Bullish Signals
Sales and EPS beat expectations on volume growth.
Risk Factors
Lower Q4 profitability expected due to higher costs and reinvestment needs.
Sale impacts results until deal closes in Q2 2027.
Bullish Signals
IFF beat third-quarter sales and adjusted EPS expectations driven by broad-based volume growth across its divisions.
Segment adjusted EBITDA rose 6% overall, led by a strong 10% growth in the Scent division and 7% in Taste.
Analysts raised their average 12-month price target to $98.25 from $97.62, implying approximately 7% upside from the Nov. 3 close.
The company successfully completed its $500 million accelerated share repurchase program.
Currency-neutral sales growth was reported across Taste, Scent, and Health & Biosciences segments.
Risk Factors
Management flagged lower Q4 profitability expectations due to higher costs and reinvestment needs in the Health & Biosciences segment.
The sale of the Food Ingredients business will be classified as discontinued operations, impacting reported results until the deal closes in Q2 2027.
International Flavors & Fragrances (IFF) is currently the subject of renewed investor interest following a strategic plan to utilize cash from its pending Food Ingredients sale to reduce debt by late 2027. Concurrently, the company has authorized a new $2.5 billion share repurchase program, signaling a dual focus on balance sheet repair and potential capital returns to shareholders.
The stock has demonstrated significant recent momentum, with a one-year total shareholder return of 46.03% and a three-year gain of 48.29%. Analysts from Simply Wall St currently rate the company as modestly undervalued, assigning it a fair value of $95.66 against a recent closing price of $94.15. This valuation suggests the market may be pricing in a transition toward over $1 billion in further debt reduction and higher free cash flow generation from core segments.
Despite the positive outlook driven by deleveraging, specific risks remain that could undermine the recovery narrative. Weak performance within the Health & Biosciences segment and soft demand in key markets, particularly North America and China, pose potential headwinds. Additionally, IFF trades at a sales multiple of 2.2x, which is higher than both its peers (2.0x) and the broader US Chemicals group (1.0x), creating a premium that could compress if sentiment regarding the deleveraging story cools.
π IFF plans debt reduction using Food Ingredients sale proceeds by late 2027.
π° Company authorized new $2.5 billion share repurchase program alongside debt cuts.
π Stock delivered 46.03% one-year return and 48.29% three-year gain showing recovery.
π‘ Analysts rate stock modestly undervalued with fair value of $95.66 vs $94.15 close.
π Weak Health & Biosciences performance poses specific risk to overall recovery narrative.
π IFF has received fresh attention due to plans to use proceeds from its pending Food Ingredients sale to reduce debt by late 2027.
π° The company has authorized a new $2.5 billion share repurchase program alongside its debt reduction strategy.
π IFF recorded a one-year total shareholder return of 46.03% and a three-year gain of 48.29%, indicating a strong recovery story.
π‘ Analysts rate the stock as modestly undervalued with a calculated fair value of $95.66 versus a recent close of $94.15.
π Weak performance in the Health & Biosciences segment poses a specific risk to the company's overall recovery narrative.
π Soft demand in key markets, specifically North America and China, could hinder future growth expectations for IFF.
πΈ The stock trades at a 2.2x sales multiple, which is a premium compared to peers at 2.0x and the broader US Chemicals group at 1.0x.
Bullish Signals
Authorized $2.5B share repurchase program to return capital.
Risk Factors
Health & Biosciences segment weakens recovery narrative.
Soft demand in North America and China risks revenue.
2.2x sales multiple is a premium vs peers.
Bullish Signals
International Flavors & Fragrances has authorized a $2.5 billion share repurchase program to return capital to shareholders.
The company plans to use cash from its pending Food Ingredients sale to reduce debt by late 2027, improving its balance sheet.
IFF has delivered strong recent performance with a one-year total shareholder return of 46.03% and a three-year gain of 48.29%.
Risk Factors
Weak performance in the Health & Biosciences segment could undermine the broader recovery narrative for the company.
Soft demand in key markets, specifically North America and China, presents a risk to future revenue growth.
The stock trades at a 2.2x sales multiple, which is a premium compared to peers and the broader sector, creating potential downside if sentiment cools.
Analyst Argus raised its price target for International Flavors & Fragrances (NYSE:IFF) to $95.00 from $85.00, maintaining a 'buy' rating and implying approximately 13.1% upside from the prior close. The brokerage's action contributes to a broader consensus of 'Moderate Buy' among twelve analysts with buy ratings and seven with hold ratings, averaging a price target of $91.99.
IFF reported mixed quarterly results that missed Wall Street expectations, posting adjusted earnings per share of $0.82 against a consensus of $1.07 and revenue of $1.95 billion versus a forecast of $2.62 billion. Despite the miss, the company's financial health remains robust with a current ratio of 2.06, a quick ratio of 1.72, and a low debt-to-equity ratio of 0.34, while revenue grew 1.8% year-over-year.
To support its share price following the earnings miss, IFF's board authorized a $2.5 billion share buyback program, allowing the repurchase of up to 12.1% of outstanding shares. This move signals management's confidence in the stock's valuation and commitment to returning capital to shareholders, even as insider selling activity from executives like EVP Michael Deveau and CAO Marc Birenkrant occurred during the period.
π Argus raised IFF price target to $95.00 with a 'buy' rating.
π IFF missed quarterly EPS and revenue expectations significantly.
π° Company authorized $2.5 billion share buyback program.
ποΈ Strong balance sheet with current ratio of 2.06 and low debt.
π Insiders sold shares while hedge funds increased positions.
π Argus raised IFF's price target to $95.00 with a 'buy' rating, indicating 13.1% upside from the previous close.
π The company missed quarterly expectations with adjusted EPS of $0.82 versus $1.07 expected and revenue of $1.95 billion versus $2.62 billion forecast.
π° IFF authorized a $2.5 billion share buyback program to repurchase up to 12.1% of its outstanding shares.
π Financial metrics show a strong balance sheet with a current ratio of 2.06, quick ratio of 1.72, and debt-to-equity ratio of 0.34.
π Revenue grew 1.8% year-over-year to $1.95 billion, though the company reported a net margin of 2.78% and return on equity of 7.11%.
π’ The stock trades at a P/E ratio of 77.06 with a market capitalization of $21.43 billion and a beta of 0.91.
π Insider selling activity included EVP Michael Deveau reducing his holdings by 62.93% and CAO Marc Birenkrant decreasing ownership by 22.49%.
ποΈ Institutional investors own 96.02% of the company's stock, with hedge funds like Root Financial Partners increasing positions significantly.
Bullish Signals
Argus raised price target to $95.00 with 'buy' rating.
Risk Factors
Missed EPS expectations at $0.82 vs $1.07 consensus.
Revenue fell short at $1.95B vs $2.62B expected.
Executives sold stakes; EVP Deveau reduced by 62.93%.
Bullish Signals
Argus raised the price target to $95.00 from $85.00 while maintaining a 'buy' rating, implying 13.1% upside.
The company authorized a substantial $2.5 billion share buyback program, allowing repurchase of up to 12.1% of outstanding shares.
IFF maintains a strong balance sheet with a current ratio of 2.06, quick ratio of 1.72, and low debt-to-equity ratio of 0.34.
Revenue grew 1.8% year-over-year to $1.95 billion, demonstrating underlying business growth despite the earnings miss.
The stock has a market capitalization of $21.43 billion and trades below its 52-week high of $89.32.
Risk Factors
The company missed quarterly adjusted EPS expectations, reporting $0.82 versus the consensus estimate of $1.07.
Revenue fell short of analyst forecasts at $1.95 billion compared to the expected $2.62 billion.
Executives engaged in insider selling, with EVP Michael Deveau reducing his stake by 62.93% and CAO Marc Birenkrant by 22.49%.
International Flavors & Fragrances Inc. (IFF) operates as a global specialty ingredients company serving consumer goods, food and beverage, health, home care, personal care, and pharmaceutical markets. The firm develops formulations that influence product taste, smell, feel, function, and performance for major brand owners. Its core capabilities span flavors for beverages, dairy, and savory foods, as well as fragrances used in perfumes, detergents, and household products.
IFF maintains a significant health and biosciences platform offering enzymes, cultures, probiotics, and biotechnology-based ingredients for dietary supplements, food production, animal nutrition, and industrial processes. The company's food ingredients portfolio includes texturants, emulsifiers, and plant-based proteins designed to shape texture and mouthfeel. These businesses rely on proprietary recipes, sensory research, regulatory expertise, and long-term customer relationships within a competitive industry.
Analyst sentiment remains strongly positive with 67% of analysts rating IFF as a Buy, while no rating changes were recorded over the last 30 days. Technical indicators show the stock price trading above both the 50-day and 200-day moving averages, indicating a strong long-term trend despite weakening MACD momentum. However, insider selling represents a notable negative factor, with insiders net selling approximately $840K in stock over the last 90 days without meaningful purchases.
π Serves consumer goods, food, health, and pharmaceutical markets with proprietary formulations.
𧬠Operates a significant biosciences platform offering enzymes, cultures, and biotech ingredients.
π Strongly positive sentiment with 67% of analysts rating IFF as a Buy.
π° Insider selling is the main negative factor with $840K net sales in 90 days.
π IFF serves consumer goods, food and beverage, health, home care, personal care, and pharmaceutical markets with proprietary flavor and fragrance formulations.
𧬠The company operates a significant health and biosciences platform providing enzymes, cultures, probiotics, and biotechnology-based ingredients for various applications.
π Analyst sentiment is strongly positive with 67% of analysts rating International Flavors & Fragrances as a Buy.
π Technical signals indicate a strong long-term trend as the stock price trades above both the 50-day and 200-day moving averages.
π° Insider selling is identified as the main negative factor, with net sales of approximately $840K recorded over the last 90 days.
π No rating changes were recorded for IFF over the last 30 days, reflecting stable analyst consensus.
Bullish Signals
67% of analysts rate IFF as a Buy.
Stock trades above 50-day and 200-day moving averages.
Risk Factors
Insiders net sold $840K in stock over last 90 days.
Bullish Signals
Analyst sentiment remains strongly positive with 67% of analysts rating International Flavors & Fragrances as a Buy.
Technical indicators show the stock price trading above both the 50-day and 200-day moving averages, indicating a strong long-term trend.
Risk Factors
Insider selling is the main negative factor, with insiders net selling approximately $840K in stock over the last 90 days without meaningful purchases.
International Flavors & Fragrances (IFF) reported a Q2 2026 earnings miss, with revenue reaching USD 1.95 billion against a consensus estimate of USD 2.62 billion. Adjusted EPS came in at USD 0.82, falling short of the expected USD 1.07. Despite the quarterly shortfall, year-over-year revenue still increased by 1.8%, indicating underlying volume growth as the company navigates portfolio-related costs and attempts to convert that growth into stronger profitability.
Management raised the low end of its full-year 2026 sales outlook for continuing operations to a range of USD 7.4 billion to USD 7.6 billion, representing 2% to 4% growth. This revision is an improvement over the previously guided range of 1% to 4%. Additionally, the company forecast EBITDA between USD 1.53 billion and USD 1.6 billion, signaling a strategic shift toward execution where volume remains the primary driver while productivity efforts aim to offset rising input costs.
At the close on September 23, 2026, IFF shares traded at USD 85.71, trading below its 52-week high of USD 89.32 but above its low of USD 59.14. The company maintains a market capitalization of approximately USD 21.88 billion. Analysts tracked by MarketBeat maintain a Moderate Buy consensus with an average 12-month price target of USD 91.40, suggesting the market views the quarterly miss as manageable given the improved full-year guidance and continued volume expansion.
π Q2 2026 revenue missed consensus at USD 1.95B vs USD 2.62B.
π° Adjusted EPS of USD 0.82 fell short of USD 1.07 expectation.
MCH Advisory Research has issued a SELL rating on International Flavors & Fragrances Inc (IFF), setting a 12-month probability-weighted target price of $74, which represents a 13% downside from the current spot price of $85.79. The firm's triangulated fair value is estimated at $63.96, implying a -25% discount to market levels. This valuation verdict is primarily driven by concerns over gross margin sustainability and a legacy asset base where depreciation significantly exceeds capital expenditure, signaling a harvesting rather than expansion strategy.
The report identifies gross margin as the single most critical variable, explaining 65% of the Monte Carlo simulation's outcome variance. The analyst model highlights that the company recently reported a net loss for the full year and carries approximately $5.2B in net debt, limiting its ability to weather a raw-material squeeze or demand slump. While the market currently values IFF at roughly 19x forward earnings, the house DCF model utilizes a terminal multiple of only 14x, suggesting the stock is priced for an optimistic growth trajectory that may not materialize given structural headwinds.
The research outlines a scenario tree ranging from a structural downside case of $33.70 to a bull case of $132, with the probability-weighted blend landing at $74.25 after adjusting for stock-based compensation dilution. Key risks include an industrial recession complex that could erode volumes and pricing power while input costs rise. The report notes that management sentiment is currently elevated relative to analyst floors, flagging this as a potential disconfirmation signal given the underlying valuation concerns and narrow moat exacerbated by post-merger integration overhangs.
π MCH Advisory rates IFF SELL with $74 target price.
π° Company reported net loss for most recent full year.
ποΈ Depreciation expenses exceed capital expenditure, harvesting assets.
βοΈ Gross margin drives 65% of valuation outcome variance.
πΈ Net debt of $5.2B limits flexibility against squeezes.
π MCH Advisory Research rates IFF as SELL with a 12-month probability-weighted target of $74, implying a 13% downside from the current price of $85.79.
π° The company reported a net loss at the bottom line for the most recent full year, raising concerns about profitability and absorptive capacity.
ποΈ Depreciation expenses currently run well above capital expenditure, indicating the asset base is being harvested rather than renewed or expanded.
βοΈ Gross margin explains 65% of the Monte Carlo outcome variance, making it the dominant driver of valuation uncertainty and downside risk.
πΈ Net debt stands at approximately $5.2B, which limits the company's flexibility to respond to a sustained raw-material squeeze or demand contraction.
π The house DCF model values shares at $47.98 using an 8.5% WACC and a 14x terminal multiple, significantly below the current market price.
π Management sentiment is flagged as elevated (+0.58 delta) relative to analyst floors, serving as a disconfirmation watch signal for the bearish thesis.
π The scenario tree includes a structural downside case of $33.70 driven by brand/volume erosion and margin compression risks.
π‘οΈ The report suggests a Bear Put Spread options strategy to express the defined-risk downside view without shorting the stock directly.
π Peer median forward P/E multiples imply a value of $108, but this is weighted lightly in the final model as multiple risk rather than a base case.
Bullish Signals
Narrow moat from customer lock-in in flavors/fragrances.
Scale advantages in health/biosciences offer growth.
The company possesses a narrow moat derived from customer formulation lock-in in flavors and fragrances segments with regulatory-registered specifications.
Scale advantages exist within the health and biosciences segments, providing a potential growth vector if market conditions improve.
Risk Factors
The company reported a loss at the net line for the most recent full year, indicating immediate profitability challenges.
Depreciation expenses currently exceed capital expenditure, signaling that the legacy asset base is being harvested rather than expanded.
A sustained raw-material squeeze poses the single most damaging risk, capable of compressing margins while high net debt limits defensive responses.
The company carries approximately $5.2B in net debt, which mechanically increases leverage as operating profits fall during a downturn.
Management sentiment is unusually upbeat relative to analyst floors, flagged as a disconfirmation signal given the bearish valuation thesis.
The house DCF model values shares at $47.98, implying the stock is trading rich by roughly 3.5 percentage points of revenue CAGR compared to intrinsic value.
International Flavors & Fragrances Inc. (NYSE: IFF) reported second-quarter earnings that missed analyst expectations, posting $0.82 per share versus the consensus of $1.07 and revenue of $1.95 billion against estimates of $2.62 billion. Despite the miss, the company's shares opened near their 52-week high of $89.32 at $86.99, reflecting mixed market sentiment regarding its performance in the specialty chemicals sector.
To support shareholder value following the earnings miss, IFF's Board of Directors approved a new $2.5 billion share-repurchase program and maintained its quarterly dividend at $0.40 per share. The buyback authorization allows the company to purchase up to 12.1% of its outstanding stock, signaling management's belief that shares are undervalued despite the recent financial underperformance.
Analyst sentiment remains cautiously optimistic with a consensus 'Moderate Buy' rating and an average price target of $91.40. While some institutions like Nykredit A/S increased their stakes significantly, insider selling activity totaling over $1.3 million in the last 90 days suggests caution among company executives regarding current valuation levels.
π IFF missed Q2 earnings and revenue estimates significantly.
π° Company approved $2.5 billion share repurchase program.
π Shares traded near 52-week high despite weak results.
π¦ Nykredit A/S added $223 million stake to holdings.
πΈ Insiders sold $1.32 million in shares recently.
π IFF reported Q2 earnings of $0.82 per share, missing the $1.07 consensus estimate, while revenue of $1.95 billion fell short of the $2.62 billion forecast.
π° The company approved a $2.5 billion share-repurchase program to return capital to shareholders and offset the recent earnings miss.
π IFF shares opened at $86.99, trading near their 52-week high of $89.32 despite the disappointing quarterly financial results.
π¦ Institutional ownership remains strong at 96.02%, with Nykredit A/S purchasing a new stake worth approximately $223 million.
πΈ Insiders sold 15,543 shares worth about $1.32 million over the past 90 days, indicating some executive caution.
π Analysts maintain a consensus 'Moderate Buy' rating with an average price target of $91.40 for the stock.
International Flavors & Fragrances Inc. (IFF) operates as a global specialty ingredients company serving diverse markets including consumer goods, food and beverage, health, home care, personal care, and pharmaceuticals. The firm collaborates with major brand owners to develop formulations that are central to consumer preference, product stability, nutrition, and manufacturing efficiency across various finished products.
IFF is renowned for its taste and scent capabilities, creating systems for beverages, dairy, savory foods, sweet goods, fine fragrances, and household products. These businesses rely on proprietary recipes, sensory research, regulatory expertise, and long-term customer relationships. Additionally, the company maintains a significant health and biosciences platform offering enzymes, cultures, probiotics, and biotechnology-based ingredients used in dietary supplements, food production, animal nutrition, and industrial processes.
The article highlights that IFF operates in a competitive industry where innovation, scale, quality assurance, and customer collaboration are critical. Its broad portfolio provides exposure to everyday consumption categories rather than a single end market, leveraging custom formulations and technical know-how. The text concludes with a strong bullish outlook based on analyst sentiment, insider buying activity, and positive technical signals, noting the stock is trading above key moving averages.
Analyst sentiment remains strongly positive with 66% of analysts rating IFF as a Buy, while no rating changes were recorded recently. Insider activity is described as mildly supportive, with net buyers purchasing approximately $20.3M in stock over the last 90 days. Technical indicators are strongly bullish, showing the price above both 50-day and 200-day moving averages, supported by MACD momentum and a bullish RSI.
π’ Serves consumer goods, health, and pharma markets with specialty ingredients.
π Best known for taste, scent capabilities via proprietary recipes.
𧬠Operates significant health platform including enzymes, cultures, and probiotics.
π° Insiders net buyers of $20.3M stock over last 90 days.
π Technical signals bullish with price above key moving averages.
π’ IFF serves consumer goods, food, beverage, health, home care, personal care, and pharmaceutical markets with specialty ingredients.
π The company is best known for taste and scent capabilities in flavors and fragrances relying on proprietary recipes and sensory research.
𧬠IFF operates a significant health and biosciences platform including enzymes, cultures, probiotics, and biotechnology-based ingredients.
π€ Custom formulations and technical know-how are central to the business model across everyday consumption categories.
π Analyst sentiment is strongly positive with 66% of analysts rating International Flavors & Fragrances as a Buy.
π° Insiders were net buyers of approximately $20.3M in stock over the last 90 days, signaling mild support.
π Technical signals are strongly bullish with the price trading above both 50-day and 200-day moving averages.
π MACD momentum is supportive while RSI indicates a bullish trend for the stock.
π No recent news events were linked to this specific listing in the provided text.
Bullish Signals
66% of analysts rate International Flavors & Fragrances as a Buy.
Insiders bought $20.3M net over last 90 days.
Strong long-term bullish trend indicated by technical signals.
Stock price above 50-day and 200-day moving averages.
Bullish MACD momentum supports current upward price movement.
Bullish Signals
Analyst sentiment remains strongly positive with 66% of analysts rating International Flavors & Fragrances as a Buy.
Insider buying activity is dominant, with net purchases of approximately $20.3M over the last 90 days.
Technical signals are strongly bullish, indicating a strong long-term trend.
The stock price is currently above both the 50-day and 200-day moving averages.
MACD momentum indicators are supportive of the current upward price movement.
RSI technical indicator is showing a bullish signal for the stock.
International Flavors & Fragrances Inc. (NYSE: IFF) is evaluated as a top-tier basic materials stock, ranking 10th on a list of ten best-in-class picks compiled by Insider Monkey. The company operates as the world's largest specialty ingredient producer, serving food, beverage, health, home goods, personal care, and pharmaceutical sectors with proprietary formulas and unique solutions.
Despite previous shareholder value erosion due to overpayment for acquisitions like DuPont Nutrition Sciences and Frutarom, IFF has demonstrated a remarkable recovery. The company reported record second-quarter 2024 adjusted EBITDA growth of 15% year-over-year, driven by high single-digit volume growth across its flavors, fragrances, and health divisions.
Looking ahead, IFF has raised its full-year outlook, projecting sales between $11.1 billion and $11.3 billion, an increase from the prior range of $10.8 billion to $11.1 billion. Adjusted operating EBITDA is expected to rise to a range of $2.1 billion to $2.17 billion, signaling strong growth potential and continued value creation for shareholders in the specialty chemicals industry.
The article notes that Millennium Management holds the largest stake among hedge funds with over 4.3 million shares valued at $411.32 million as of Q2 2024. While IFF is a solid investment, the publication suggests AI stocks may offer higher returns in shorter timeframes, though IFF remains a significant player in basic materials.
π IFF ranks 10th on Insider Monkey's best basic materials stocks list.
π° Full-year sales guidance raised to $11.1 billionβ$11.3 billion range.
𧬠Health and biosciences segment accounts for nearly 25% of revenue.
π Major acquisitions include DuPont nutrition (2021) and Frutarom (2018).
π International Flavors & Fragrances (IFF) ranks 10th on Insider Monkey's list of the best basic materials stocks to buy now.
π The company achieved record second-quarter 2024 adjusted EBITDA growth of 15% year-over-year driven by volume expansion.
π° IFF has raised its full-year sales guidance to $11.1 billionβ$11.3 billion, up from the previous range of $10.8 billionβ$11.1 billion.
π Adjusted operating EBITDA is projected to increase to a range of $2.1 billionβ$2.17 billion for the full year.
𧬠The health and biosciences segment accounts for nearly 25% of total revenue, leading in probiotics and enzymes globally.
π« About half of IFF's sales come from its nourish business, which includes plant-based proteins and texturants.
π Major acquisitions include DuPont's nutrition and biosciences businesses (2021) and Frutarom (2018).
β οΈ Shareholder value previously suffered due to overpayment for the Frutarom and DuPont Nutrition Sciences acquisitions.
π The broader basic materials sector saw a 10.40% year-to-date return, with specialty chemicals holding 41.75% market weight.
π¬ Sustainability initiatives include circular ecosystems, bio-based feedstocks, and chemical recycling to reduce emissions.
ποΈ Millennium Management is the largest hedge fund stakeholder with 4,320,107 shares worth $411.32 million as of Q2 2024.
π IFF collaborates with clients to provide unique solutions across food, beverage, health, and personal care industries.
Bullish Signals
Record Q2 adjusted EBITDA growth of 15% year-over-year.
Raised full-year sales guidance to $11.1 billionβ$11.3 billion.
Full-year adjusted operating EBITDA expected at $2.1 billionβ$2.17 billion.
World's largest specialty ingredient producer with diverse portfolio.
Health segment accounts for nearly 25% of total revenue.
Risk Factors
Overpayment for Frutarom and DuPont Nutrition Sciences hurt shareholder value.
Cyclical sector tied to economic conditions with recession worries.
China's shift to electric arc furnaces may reduce iron ore demand.
Bullish Signals
IFF reported record second-quarter 2024 adjusted EBITDA growth of 15% year-over-year driven by high single-digit volume growth.
The company has raised its full-year sales guidance to $11.1 billionβ$11.3 billion, an increase from the prior range of $10.8 billionβ$11.1 billion.
Adjusted operating EBITDA is expected to rise to a range of $2.1 billionβ$2.17 billion for the full year.
IFF is the world's largest specialty ingredient producer with a diverse portfolio across food, beverage, health, and personal care sectors.
The health and biosciences segment accounts for nearly 25% of total revenue and leads globally in probiotics and enzymes.
Millennium Management holds a significant stake of 4.3 million shares valued at $411.32 million as of Q2 2024, indicating strong institutional confidence.
Risk Factors
Shareholder value previously suffered due to overpayment for the acquisitions of Frutarom and DuPont Nutrition Sciences.
The broader basic materials sector is cyclical and tied to economic conditions, with recession worries affecting market sentiment.
China's shift toward electric arc furnace steel production may reduce long-term demand for iron ore, impacting related supply chains.
International Flavors & Fragrances (IFF) has agreed to sell a significant portfolio of businesses including botanical extracts, vitamins, minerals, natural colors, antioxidants, and specific flavor operations in Peru to SuanNutra. SuanNutra is a portfolio company of Carbyne Equity Partners, with the transaction facilitated by financial advisor Alantra and legal counsel DLA Piper LLP.
The divested business units serve diverse food, beverage, and nutritional markets through tailored solutions. The portfolio generated approximately $170 million in revenue during 2025 and employs roughly 600 individuals across five production sites located in Europe, the United States, and Latin America.
IFF anticipates finalizing the sale by the close of 2026, subject to standard closing conditions including regulatory approvals and necessary consultation processes. The financial specifics of the transaction value remain undisclosed at this time.
π€ IFF agrees to divest botanical extracts, vitamins, and flavor operations.
π’ SuanNutra, owned by Carbyne Equity Partners, is the buyer.
π° Portfolio generated $170 million revenue in 2025 fiscal year.
π₯ Operations employ 600 people across five sites globally.
π Transaction expected to close by end of 2026.
π€ IFF has reached a definitive agreement to divest its botanical extracts, vitamins, food enhancement, natural colors, and certain Peru flavor operations.
π’ The buyer is SuanNutra, a Madrid-based portfolio company owned by German private equity firm Carbyne Equity Partners.
π° The targeted business portfolio generated approximately $170 million in revenue during the 2025 fiscal year.
π₯ The divested operations collectively employ roughly 600 individuals across five production sites spanning Europe, the U.S., and Latin America.
π IFF expects to finalize the transaction by the close of 2026 pending regulatory approvals and standard closing conditions.
ποΈ Alantra served as the financial advisor for IFF while DLA Piper LLP provided legal counsel for the deal.
Bullish Signals
Divestiture unlocks value for reinvestment or debt reduction.
Sells $170M revenue stream with 600 employees.
Risk Factors
Undisclosed sale price prevents assessing premium/discount vs. market.
Bullish Signals
π° The divestiture allows IFF to unlock value from non-core assets, potentially freeing up capital for strategic reinvestment or debt reduction.
π Selling a $170 million revenue stream with 600 employees suggests the company is successfully managing its portfolio size and focusing on core competencies.
Risk Factors
π The financial specifics of the sale price remain undisclosed, preventing immediate assessment of whether the deal represents a premium or discount relative to market expectations.
Bank of New York Mellon Corp increased its stake in International Flavors & Fragrances Inc. (NYSE:IFF) by 0.7% in the first quarter, purchasing an additional 10,654 shares to hold a total position valued at approximately $115.98 million. This move aligns with several other major institutional investors who recently added to their holdings, including State Street Corp, First Eagle Investment Management LLC, Invesco Ltd., Geode Capital Management LLC, and UBS Asset Management Americas, which collectively increased their stakes significantly during the fourth quarter.
The company reported strong financial performance in its latest earnings released on May 5th, beating analyst expectations with $1.25 per share in earnings compared to a consensus of $1.08. Revenue reached $2.74 billion, surpassing estimates of $2.64 billion, though it declined 3.6% year-over-year. The firm maintains a healthy return on equity of 7.65% and a net margin of 7.78%, while also declaring a quarterly dividend of $0.40 per share paid to stockholders of record as of June 18th.
Analyst sentiment remains largely positive, with UBS Group raising its price target to $86.00, JPMorgan Chase increasing its target to $92.00, and Citigroup setting a 'buy' rating at $88.00. Director Paul J. Fribourg also made a notable purchase of 260,000 shares in June for approximately $19.3 million, bringing his direct ownership to over 2.68 million shares. MarketBeat aggregates thirteen buy ratings and five hold ratings, with an average price target of $91.16.
π Bank of New York Mellon added 10,654 shares worth $115.98 million in Q1.
π¦ State Street Corp owns over 11 million shares valued at $751.87 million.
π First Eagle Investment Management boosted holdings by 27.5% with nearly 1.9 million shares.
π° IFF reported Q1 EPS of $1.25, beating estimates and topping revenue expectations.
π Revenue declined 3.6% year-over-year to $2.74 billion while maintaining strong margins.
π Bank of New York Mellon Corp increased its IFF position by 0.7% in Q1, adding 10,654 shares to a total holding valued at $115.98 million.
π¦ State Street Corp grew its stake by 1.1% in Q4, now owning over 11 million shares worth $751.87 million.
π First Eagle Investment Management LLC significantly boosted its holdings by 27.5% in Q4, acquiring nearly 1.9 million additional shares.
π° IFF reported Q1 earnings of $1.25 per share, beating analyst estimates of $1.08 and topping revenue expectations at $2.74 billion.
π Revenue declined 3.6% year-over-year to $2.74 billion, though the company maintained a 7.65% return on equity and 7.78% net margin.
π΅ The company declared a quarterly dividend of $0.40 per share, resulting in an annualized yield of 2.1% with a payout ratio of 48.93%.
π UBS Group raised its price target from $75.00 to $86.00 following a research report on May 7th.
π Citigroup lowered its price target to $88.00 but maintained a 'buy' rating in a June 24th report.
π JPMorgan Chase increased its price target from $90.00 to $92.00 and assigned an 'overweight' rating.
π Director Paul J. Fribourg purchased 260,000 shares in June for $19.3 million, increasing his direct ownership by 10.73%.
π MarketBeat reports an average analyst price target of $91.16 based on thirteen buy ratings and five hold ratings.
π IFF operates a global R&D network across North America, Europe, Asia-Pacific, and Latin America focusing on aroma chemistry and biotechnology.
International Flavors & Fragrances Inc. (NYSE:IFF) recently received an average broker recommendation of 'Moderate Buy' with a 12-month price objective of $91.16, according to MarketBeat.com. While five analysts hold the stock, thirteen have assigned buy or overweight ratings. Notable recent analyst actions include Citigroup lowering its target to $88.00, JPMorgan Chase raising it to $92.00, Benchmark initiating coverage with a $100.00 target, Jefferies Financial Group increasing its target to $105.00, and Morgan Stanley lifting its target to $95.00.
Institutional investor activity shows mixed signals for the specialty chemicals company during the first quarter. Several funds increased their stakes, with Empowered Funds LLC growing its position by 71.5% and Geneos Wealth Management Inc. increasing holdings by 55.7%. However, hedge fund ownership remains high at 96.02%, indicating significant institutional interest despite recent price fluctuations.
Financially, IFF reported strong quarterly earnings of $1.25 per share, beating the consensus estimate of $1.08, with revenue reaching $2.74 billion against expectations of $2.64 billion. The company maintains a market cap of $19.99 billion and a dividend yield of 2.0%. Analysts project full-year earnings of $4.55 per share, though year-over-year revenue declined by 3.6%.
π Broker consensus is 'Moderate Buy' with a $91.16 price target.
π¦ Institutional ownership reaches 96.02% as funds increase stakes.
π΅ Quarterly dividend of $0.40 offers a 2.0% annualized yield.
π Full-year earnings are expected to hit $4.55 per share.
π IFF shares have an average broker recommendation of 'Moderate Buy' with a 12-month price objective of $91.16.
π Analysts show divergent views, with Citigroup lowering its target to $88.00 while Jefferies raised its target to $105.00.
π° The company reported Q1 earnings of $1.25 EPS, beating the consensus estimate of $1.08.
π Revenue for the quarter was $2.74 billion, representing a 3.6% decline compared to the prior year.
π¦ Institutional ownership stands at 96.02%, with several funds like Empowered Funds LLC increasing their stakes significantly.
π΅ IFF pays a quarterly dividend of $0.40 per share, resulting in an annualized yield of 2.0%.
π Analysts expect full-year earnings to reach $4.55 per share for the current fiscal year.
π The company operates global innovation centers across North America, Europe, Asia-Pacific, and Latin America.
Bullish Signals
EPS beat consensus at $1.25 vs $1.08.
Revenue reached $2.74B, beating estimates of $2.64B.
Jefferies raised target to $105; Morgan Stanley to $95.
Institutional holdings grew 71.5% and 55.7% respectively.
Dividend yield stands at 2.0% with $1.60 annual payout.
Risk Factors
Price target cut from $96 to $88.
Revenue declined 3.6% year-over-year.
Elevated P/E ratio of 23.94.
Bullish Signals
IFF reported Q1 earnings of $1.25 EPS, which beat the consensus estimate of $1.08 by $0.17.
Revenue for the quarter reached $2.74 billion, exceeding analyst expectations of $2.64 billion.
Multiple major brokerages have raised or initiated buy ratings, including Jefferies Financial Group raising its target to $105.00 and Morgan Stanley lifting its target to $95.00.
Several institutional investors increased their holdings in the first quarter, with Empowered Funds LLC growing its position by 71.5% and Geneos Wealth Management Inc. increasing by 55.7%.
The company maintains a healthy dividend yield of 2.0% with an annualized payout of $1.60 per share.
Risk Factors
Citigroup decreased its price objective on IFF shares from $96.00 to $88.00 in a recent research note.
The company's revenue declined by 3.6% year-over-year during the reported quarter.
The stock trades at a P/E ratio of 23.94, which may be considered elevated depending on sector comparisons.
International Flavors & Fragrances Inc. (NYSE:IFF) has received a consensus 'Moderate Buy' rating from eighteen analysts, with thirteen issuing buy recommendations and five holding the stock. The average 12-month price target stands at $91.16. Recent brokerages including Jefferies, Barclays, and Oppenheimer have raised their price targets to between $90 and $105, citing positive outlooks, while Benchmark initiated coverage with a buy rating and $100 target.
Financially, IFF reported strong quarterly earnings on May 5th, beating consensus estimates with $1.25 EPS against an expectation of $1.08 and revenue of $2.74 billion versus $2.64 billion expected. The company achieved a net margin of 7.78% and a return on equity of 7.65%. However, quarterly revenue declined 3.6% year-over-year. Analysts forecast full-year EPS of $4.55.
Institutional ownership remains high at 96.02%, with several funds increasing stakes in the fourth quarter, including DNB Asset Management and State of Michigan Retirement System. The company recently paid a quarterly dividend of $0.40 per share on June 18th, resulting in an annualized yield of 2.1% and a payout ratio of 48.93%. IFF operates as a global leader in flavors, fragrances, and cosmetic actives across food, beverage, and pharmaceutical sectors.
π Consensus 'Moderate Buy' rating with $91.16 price target.
π Jefferies raised target to $105 in late May reports.
π° Q1 EPS beat expectations at $1.25 versus $1.08 consensus.
International Flavors & Fragrances (IFF) has arranged a US$1 billion senior unsecured delayed draw term loan, a move closely linked to refinancing its 2026 notes and the planned sale of its Food Ingredients business. This strategic balance sheet reshaping aims to increase flexibility while the company pivots toward differentiated, higher-margin products.
The stock is currently trading at US$76.35, reflecting a year-to-date gain of 12.23% despite a five-year total shareholder return decline of 41.78%. Analysts suggest the current valuation may be undervalued with a narrative fair value of US$91.66, driven by expectations of future margin expansion and earnings quality improvements following recent divestitures.
IFF has recently exited commodity businesses including Pharma Solutions, Soy Crush, Concentrates, and Lecithin to focus on innovation-driven segments. However, investors must weigh these optimistic growth prospects against execution risks in the Food Ingredients segment and ongoing pricing pressure within the fragrance ingredients market.
π¦ IFF refinances with US$1 billion delayed draw term loan.
πΌ Company plans to sell Food Ingredients business unit.
π Shares trade at US$76.35, undervalued by 16.7% per analysts.
π Divestitures shift focus to higher-margin innovation-driven products.
β οΈ Execution risks and pricing pressure pose transition challenges.
π¦ IFF has secured a US$1 billion senior unsecured delayed draw term loan to refinance existing 2026 notes.
πΌ The company plans to sell its Food Ingredients business as part of a broader portfolio reshaping strategy.
π Shares trade at US$76.35, showing a 12.23% year-to-date return but lagging with a -41.78% five-year total shareholder return.
π― Analysts assign a narrative fair value of US$91.66, labeling the current setup as undervalued at 16.7%.
π Recent divestitures of commodity businesses aim to shift focus toward higher-margin, innovation-driven products.
β οΈ Execution risks in the Food Ingredients segment remain a key concern for investors during the transition.
π Pricing pressure in the fragrance ingredients sector could challenge the upbeat growth narrative.
Bullish Signals
Refinancing debt and selling assets to improve financial flexibility.
Pivoting to higher-margin innovation-driven products for future expansion.
Undervalued by ~16.7% with fair value of US$91.66.
Risk Factors
Execution risks in Food Ingredients segment during strategic evaluation.
Pricing pressure in fragrance ingredients impacts revenue and margins.
Bullish Signals
IFF is executing a strategic balance sheet reshaping that includes refinancing debt and selling non-core assets to improve financial flexibility.
The company is pivoting away from low-margin commodity businesses toward differentiated, higher-margin, innovation-driven products which supports future margin expansion.
Analysts calculate a narrative fair value of US$91.66 against the current trading price of US$76.35, suggesting the stock is undervalued by approximately 16.7%.
Risk Factors
IFF faces execution risks specifically within its Food Ingredients segment as it undergoes a strategic evaluation and potential sale.
The company is subject to ongoing pricing pressure in the fragrance ingredients market, which could impact revenue growth and margins.
International Flavors & Fragrances Inc. (IFF) shares rallied 1.69% to close at $76.35 on Friday, demonstrating relative strength in a broadly negative market environment where the S&P 500 fell 0.05% and the Dow Jones Industrial Average dropped 0.09%.
Despite the intraday gains, IFF remains 9.59% below its 52-week high of $84.45, a peak reached on February 17th. The stock's outperformance against major indices suggests investor confidence in the company's specific fundamentals or trading dynamics despite wider market headwinds.
The article highlights the contrast between IFF's positive momentum and the general decline of the broader stock market, noting that the rally occurred during what was described as an all-around rough trading session for equities.
π IFF shares rose 1.69% to close at $76.35.
π Broader market declined as S&P 500 fell 0.05%.
π IFF outperformed competitors during the rough trading session.
π Stock closed 9.59% below its 52-week high of $84.45.
π IFF shares rallied 1.69% to close at $76.35 on Friday.
π The broader market declined with the S&P 500 falling 0.05% and the Dow Jones dropping 0.09%.
π IFF outperformed competitors during a rough trading session for the overall stock market.
π The stock closed 9.59% below its 52-week high of $84.45 set on February 17th.
π Data provided by FACTSET reflects trades reported through Nasdaq with a 15-minute delay.
Bullish Signals
IFF shares rallied 1.69% to $76.35, outperforming market declines.
Stock rose while competitors and major indices fell.
Bullish Signals
IFF shares rallied 1.69% to close at $76.35, significantly outperforming the broader market which saw declines in both the S&P 500 and Dow Jones Industrial Average.
The stock demonstrated relative strength by rising while competitors and major indices fell during a rough trading session.
SG Americas Securities LLC increased its stake in International Flavors & Fragrances Inc. (NYSE: IFF) by 62.2% in the first quarter, ending with a position of 226,822 shares valued at approximately $16.46 million. The firm purchased an additional 86,963 shares during this period, bringing its total ownership to about 0.09% of the company.
IFF reported strong quarterly financial results that exceeded analyst expectations, posting earnings per share (EPS) of $1.25 on revenue of $2.74 billion. The company maintained its quarterly dividend at $0.40 per share, implying a yield of 2.1%, and analysts generally maintain a Moderate Buy rating with an average price target of $90.58.
Several major institutional investors have recently increased their holdings in the specialty chemicals company. Notable increases include Carl Icahn raising his position by 26.7% to own roughly $292 million worth of stock, Dodge & Cox lifting holdings by 5.5%, and First Eagle Investment Management increasing its stake by 27.5%.
Director Paul J. Fribourg executed a significant insider purchase on June 1st, acquiring 260,000 shares for approximately $19.3 million, representing a 10.73% increase in his direct ownership. This transaction highlights continued confidence from corporate insiders alongside the broader institutional accumulation of shares.
π SG Americas Securities increased IFF position by 62.2% in Q1.
π° IFF reported $1.25 EPS and $2.74 billion quarterly revenue.
π¦ Major institutions including Carl Icahn increased their stakes recently.
π Director Paul J. Fribourg bought 260,000 shares for $19.3 million.
πΈ Company declared a quarterly dividend of $0.40 per share.
π SG Americas Securities LLC increased its IFF position by 62.2% in Q1, holding 226,822 shares valued at $16.46 million.
π° IFF beat earnings expectations with $1.25 EPS and $2.74 billion revenue for the quarter.
π Analysts maintain a Moderate Buy rating with an average price target of $90.58.
π¦ Major institutions including Carl Icahn, Dodge & Cox, and First Eagle increased their stakes recently.
π Director Paul J. Fribourg bought 260,000 shares for $19.3 million in a single transaction.
πΈ The company declared a quarterly dividend of $0.40 per share with a 2.1% yield.
π Revenue declined 3.6% year-over-year to $2.74 billion during the reported quarter.
π Institutional ownership stands at approximately 96.02% of the total float.
π Oppenheimer and Barclays raised their price targets to $90.00 following recent reports.
π IFF operates global innovation centers focusing on aroma chemistry and biotechnology.
Bullish Signals
EPS beat consensus at $1.25 vs $1.08 estimate.
Revenue hit $2.74B, beating the $2.64B forecast.
SG Americas increased position by 62.2% in Q1.
Carl Icahn raised stake to 4.75M shares ($292M).
Dodge & Cox holdings grew by 5.5% to $2.2B.
First Eagle lifted position by 27.5% in Q4.
Director Fribourg bought 260K shares for $19.3M.
Swiss Life grew position by 117.0% in Q4.
Analysts raised price targets to $90.00.
Quarterly dividend payout is $0.40 per share.
Risk Factors
Revenue declined 3.6% to $2.74 billion.
Price target lowered from $95.00 to $90.00.
Stock trading down 1.3%.
Bullish Signals
IFF reported quarterly EPS of $1.25, beating analyst consensus estimates of $1.08 by $0.17.
Revenue reached $2.74 billion, surpassing the forecasted $2.64 billion despite a slight year-over-year decline.
SG Americas Securities LLC significantly increased its position by 62.2% in Q1, adding 86,963 shares.
Carl Icahn raised his stake by 26.7% to own 4.75 million shares valued at approximately $292 million.
Dodge & Cox increased its holdings by 5.5%, now owning over $2.2 billion in company stock.
First Eagle Investment Management lifted its position by 27.5% during the fourth quarter.
Director Paul J. Fribourg purchased 260,000 shares for $19.3 million, increasing his direct ownership by over 10%.
Swiss Life Asset Management grew its position by 117.0% in the fourth quarter.
Analysts have raised price targets from major firms including Oppenheimer and Barclays to $90.00.
The company maintains a consistent dividend policy with a declared quarterly payout of $0.40 per share.
Risk Factors
IFF reported revenue of $2.74 billion, which represents a 3.6% decline compared to the previous year.
Deutsche Bank Aktiengesellschaft lowered its price objective from $95.00 to $90.00 in a recent report.
The stock is currently trading down 1.3% as of the latest market data.
International Flavors & Fragrances Inc. (NYSE:IFF) received an average analyst rating of 'Moderate Buy' from 18 covering firms, with 13 buy ratings and 5 hold ratings. Several major analysts, including JPMorgan, BNP Paribas Exane, Oppenheimer, Jefferies, and Citigroup, raised their price targets on the stock in reports issued on May 7th, reflecting generally positive sentiment toward the company's prospects.
The specialty chemicals company reported better-than-expected quarterly earnings, posting $1.25 per share in earnings versus the consensus estimate of $1.08, and revenue of $2.74 billion against expectations of $2.64 billion. The firm achieved a net margin of 7.78% and a return on equity of 7.65%, while also announcing a quarterly dividend of $0.40 per share payable to shareholders of record on June 18th.
Institutional ownership remains high at 96.02%, with notable insider activity as Director Paul J. Fribourg acquired 260,000 shares for approximately $19.3 million in early June, increasing his direct holdings by over 10%. While some hedge funds have reduced stakes, the company maintains a market cap of $19.63 billion and a price-to-earnings ratio of 23.52, trading above its 50-day and 200-day moving averages.
π 18 analysts rate IFF 'Moderate Buy' with 13 buys and 5 holds.
π° Company beat earnings with $1.25 EPS vs $1.08 consensus.
π Major firms raised price targets on May 7th.
π Director acquired 260,000 shares, increasing position by 10.73%.
π¦ Institutional ownership stands at 96.02% with $19.63B market cap.
π IFF received an average 'Moderate Buy' rating from 18 analysts, with 13 buys and 5 holds.
π Major firms including JPMorgan, BNP Paribas Exane, Oppenheimer, Jefferies, and Citigroup raised price targets on May 7th.
π° The company beat earnings expectations with $1.25 EPS versus $1.08 consensus and revenue of $2.74 billion versus $2.64 billion.
π IFF reported a net margin of 7.78% and a return on equity of 7.65% for the quarter.
πΈ A quarterly dividend of $0.40 per share was announced, yielding approximately 2.1% annually.
π Director Paul J. Fribourg acquired 260,000 shares in early June, increasing his position by 10.73%.
π¦ Institutional ownership stands at 96.02%, indicating strong confidence from major investors.
π Revenue declined 3.6% year-over-year to $2.74 billion during the reported quarter.
π The stock trades at a price-to-earnings ratio of 23.52 with a market cap of $19.63 billion.
π Analysts forecast 4.56 EPS for the current fiscal year, suggesting continued growth expectations.
Bullish Signals
EPS of $1.25 beat estimates of $1.08.
Revenue of $2.74B exceeded expectations of $2.64B.
Major brokerages raised price targets on May 7th.
Dividend yield is 2.1% with a 48.93% payout ratio.
Director stake increased by over 10%.
Institutional ownership stands at 96.02%.
Stock trades above 50-day and 200-day moving averages.
Risk Factors
Revenue declined 3.6% year-over-year.
Hedge funds reduced stakes recently.
Not in top five stocks for July.
Bullish Signals
IFF beat quarterly earnings estimates significantly, reporting $1.25 EPS compared to the expected $1.08.
Revenue of $2.74 billion exceeded analyst expectations of $2.64 billion for the quarter.
Multiple major brokerages including JPMorgan and BNP Paribas Exane raised their price targets on May 7th.
The company maintains a healthy dividend yield of approximately 2.1% with a payout ratio of 48.93%.
Director Paul J. Fribourg increased his stake by over 10%, signaling insider confidence in the stock.
Institutional ownership is robust at 96.02%, reflecting strong interest from hedge funds and wealth managers.
The stock is trading above both its 50-day and 200-day moving averages, indicating positive momentum.
Risk Factors
Revenue declined by 3.6% on a year-over-year basis during the reported quarter.
Some hedge funds have reduced their stakes in the company during recent quarters.
The stock has not been included in MarketBeat's top five stocks to own list for July.
International Flavors & Fragrances (IFF) is currently trading at $76.72, reflecting a 12.6% return over the last 90 days and a 6.6% total shareholder return over one year. Analysts from Simply Wall St suggest the stock is undervalued by approximately 15.4%, with a calculated fair value of $90.71 based on long-term cash flow and margin outlooks.
The company's valuation thesis relies heavily on a strategic portfolio reset, which includes divesting commodity businesses like Pharma Solutions and Soy Crush. This shift aims to focus operations on differentiated, higher-margin products within the Food Ingredients segment, thereby supporting future margin expansion and improving earnings quality compared to recent reported results.
Despite the bullish valuation narrative supported by an SWS DCF model estimating a future cash flow value of $126.04, IFF faces headwinds from weaker demand in key regions. Specific challenges persist within its Fragrance Ingredients and Food Ingredients businesses, which temper the overall optimism regarding immediate growth potential.
Investors are encouraged to weigh these strategic improvements against regional demand pressures. The article concludes that while the market may be overly cautious regarding IFF's fundamentals, the company remains a candidate for those seeking undervalued opportunities with a focus on quality and resilience.
π Stock up 12.6% in 90 days at $76.72.
π° Analysts see fair value of $90.71 (15.4% undervalued).
π Divesting commodity units to focus on higher margins.
π DCF model projects future cash flow value of $126.04.
β οΈ Facing demand pressure in key global regions.
π IFF is trading at $76.72, showing a 12.6% gain over the last 90 days and a 6.6% one-year total shareholder return.
π° Analysts estimate a fair value of $90.71, suggesting the stock is currently undervalued by approximately 15.4%.
π The company is executing a portfolio reset by divesting commodity businesses like Pharma Solutions and Soy Crush to focus on higher-margin products.
π An SWS DCF model projects a future cash flow value of $126.04, indicating the market may be pricing in excessive caution.
β οΈ IFF faces ongoing pressure from weaker demand in key global regions affecting its core operations.
π« The Food Ingredients segment is under strategic evaluation to improve margins and earnings quality.
Bullish Signals
Trading at discount to $90.71 fair value with 15.4% upside.
DCF model suggests intrinsic value of $126.04 based on cash flows.
Divestitures expected to improve margin expansion and earnings quality.
12.6% return over last 90 days indicates renewed investor interest.
Risk Factors
Weaker demand in key regions risks core revenue growth.
Fragrance and food ingredients face operational hindrances.
Bullish Signals
IFF is trading at a significant discount to its estimated fair value of $90.71, representing a potential 15.4% upside according to analyst models.
The company's DCF model suggests an intrinsic value of $126.04 based on future cash flows, implying the current market price does not fully reflect long-term earnings power.
Strategic divestitures of lower-margin commodity businesses are expected to improve overall margin expansion and earnings quality in the coming years.
Recent share price momentum includes a 12.6% return over the last 90 days, indicating renewed investor interest and market recognition.
Risk Factors
IFF is experiencing weaker demand in key regions, which poses a direct risk to revenue growth in its core markets.
The Fragrance Ingredients and Food Ingredients businesses are currently facing specific operational challenges that could hinder immediate performance improvements.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)